Published in Cell Cycle on February 05, 2007
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer (2011) 1.73
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res (2013) 1.36
Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene (2014) 1.20
Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am (2008) 1.19
BRAFV600E mutation and papillary thyroid cancer: chicken or egg? J Clin Endocrinol Metab (2012) 0.95
Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer (2014) 0.93
BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract (2012) 0.92
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Clinicopathological features of rare BRAF mutations in Korean thyroid cancer patients. J Korean Med Sci (2014) 0.85
Immune response in thyroid cancer: widening the boundaries. Scientifica (Cairo) (2014) 0.84
Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600). PLoS One (2013) 0.82
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics (2014) 0.81
Recent advances in molecular diagnosis of thyroid cancer. J Thyroid Res (2011) 0.78
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther (2016) 0.77
BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib. Int J Clin Exp Pathol (2015) 0.75
The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma – a report of a case. BMC Med Genet (2015) 0.75
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
Integrated soil-crop system management for food security. Proc Natl Acad Sci U S A (2011) 4.14
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab (2008) 2.89
Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer (2013) 2.69
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res (2007) 2.61
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab (2011) 2.06
The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle (2012) 1.98
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid (2008) 1.93
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res (2011) 1.85
Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst (2013) 1.78
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) (2012) 1.77
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Gene methylation in gastric cancer. Clin Chim Acta (2013) 1.63
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer (2006) 1.56
Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab (2009) 1.55
Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle (2013) 1.52
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab (2014) 1.52
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 1.51
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab (2007) 1.47
DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res (2005) 1.44
Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer (2012) 1.39
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer (2008) 1.39
Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res (2007) 1.39
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res (2009) 1.31
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun (2010) 1.31
Synthesis and characterization of biocompatible Fe3O4 nanoparticles. J Biomed Mater Res A (2007) 1.28
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer (2011) 1.19
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab (2007) 1.19
MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle (2009) 1.17
Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer (2011) 1.16
Chronic mild stress impairs cognition in mice: from brain homeostasis to behavior. Life Sci (2008) 1.16
BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer (2010) 1.14
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab (2007) 1.12
Prognostic significance of aberrant gene methylation in gastric cancer. Am J Cancer Res (2011) 1.10
The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun (2010) 1.08
Helicobacter pylori vacA genotypes and cagA status and their relationship to associated diseases. World J Gastroenterol (2000) 1.06
Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab (2009) 1.06
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer (2008) 1.04
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab (2011) 1.04
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab (2005) 1.04
IQGAP1 plays an important role in the invasiveness of thyroid cancer. Clin Cancer Res (2010) 1.03
BRAF V600E mutation and papillary thyroid cancer. JAMA (2013) 1.03
Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem (2013) 1.01
Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci (2012) 1.00
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr Pathol (2011) 0.99
Effect of Fgd1 on cortactin in Arp2/3 complex-mediated actin assembly. Biochemistry (2004) 0.98
Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab (2015) 0.98
BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management. Ann Surg Oncol (2009) 0.98
Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol (2013) 0.97
Genetic-targeted therapy of thyroid cancer: a real promise. Thyroid (2009) 0.97
Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer (2014) 0.96
BRAFV600E mutation and papillary thyroid cancer: chicken or egg? J Clin Endocrinol Metab (2012) 0.95
Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer (2013) 0.94
Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta (2012) 0.94
TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer. J Biomed Nanotechnol (2014) 0.92
Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors. J Clin Endocrinol Metab (2007) 0.92
Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC). Diagn Pathol (2011) 0.91
Induction of murine neonatal tolerance against Graves' disease using recombinant adenovirus expressing the TSH receptor A-subunit. Endocrinology (2011) 0.91
DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. Endocr Relat Cancer (2013) 0.91
Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer (2008) 0.90
Novel variants related to TT virus distributed widely in China. J Med Virol (2002) 0.90
TERT promoter mutations predict worse survival in laryngeal cancer patients. Int J Cancer (2014) 0.89
Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer (2013) 0.89
Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications. PLoS One (2009) 0.89
Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer. Clin Biochem (2014) 0.88
The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression. J Clin Endocrinol Metab (2014) 0.88
Non-aqueous synthesis of water-dispersible Fe3O4-Ca3(PO4)2 core-shell nanoparticles. Nanotechnology (2010) 0.88
Mitochondrial DNA alterations in thyroid cancer. J Surg Oncol (2003) 0.88
CD40 C/T(-1) and CTLA-4 A/G(49) SNPs are associated with autoimmune thyroid diseases in the Chinese population. Endocrine (2011) 0.88
Exo-Dye-based assay for rapid, inexpensive, and sensitive detection of DNA-binding proteins. Biochem Biophys Res Commun (2006) 0.87
Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma. Tumour Biol (2015) 0.86
Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells. PLoS One (2012) 0.86
Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. J Clin Endocrinol Metab (2005) 0.86
Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways. J Clin Endocrinol Metab (2013) 0.85
The N-Glycosylation Modification of LHBs (Large Surface Proteins of HBV) Effects on Endoplasmic Reticulum Stress, Cell Proliferation and its Secretion. Hepat Mon (2013) 0.83